TLSI – trisalus life sciences, inc. (US:NASDAQ)
Stock Stats
News
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
TriSalus Life Sciences (NASDAQ:TLSI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $12.00. They now have a "buy" rating on the stock.
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript [Seeking Alpha]
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 [Yahoo! Finance]
Form 8-K TriSalus Life Sciences, For: Jan 12
Form EFFECT TriSalus Life Sciences,
Form 4 TriSalus Life Sciences, For: Nov 24 Filed by: Cox Bryan F.
Form 4 TriSalus Life Sciences, For: Nov 24 Filed by: Devlin Jodi
Form 4 TriSalus Life Sciences, For: Feb 13 Filed by: Szela Mary T
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.